Master AI-Driven Innovations in CRISPR and Precision Medicine: A 3-Day Lecture Series in 4 weeks through hands-on, project-based online training with DSTC.
This 3-day lecture series, AI-Driven Innovations in CRISPR and Precision Medicine,This lecture series is designed for: ✔ Researchers & Scientists – Working in genetics, bioinformatics, AI, and biomedical sciences. ✔ Healthcare Professionals – Doctors, clinicians, and medical researchers interested in AI-driven precision medicine. ✔ Biotechnology & AI Enthusiasts – Individuals exploring the intersection of artificial intelligence and life sciences. ✔ Students & Academicians – Graduate and postgraduate students in biotechnology, bioinformatics, computational biology, and related fields. Every participant receives a verified e-Certificate and e-Marksheet from the Deep Science & Technology Consortium.
This 3-day lecture series, AI-Driven Innovations in CRISPR and Precision Medicine,This lecture series is designed for: ✔ Researchers & Scientists – Working in genetics, bioinformatics, AI, and biomedical sciences. ✔ Healthcare Professionals – Doctors, clinicians, and medical researchers interested in AI-driven precision medicine. ✔ Biotechnology & AI Enthusiasts – Individuals exploring the intersection of artificial intelligence and life sciences. ✔ Students & Academicians – Graduate and postgraduate students in biotechnology, bioinformatics, computational biology, and related fields.
1. Put AI Enablement techniques to work on real datasets and case studies.
2. Assemble a documented case study that evidences your applied capability.
• Master's and senior undergraduate students specializing in AI Enablement
• R&D engineers and working professionals applying AI Enablement in industry
• Academics and educators building research or teaching capacity in AI Enablement
• Tangible, reproducible AI Enablement work to show supervisors or employers.
• A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
• On-target activity models trained on large-scale screens and their dataset bias
• Off-target prediction models against empirical assays such as CIRCLE-seq
• Repair outcome prediction and designing an edit for a wanted allele
• ACMG/AMP classification and the persistent burden of variants of uncertain significance
• SpliceAI, AlphaMissense and where computational evidence is admissible
• Saturation genome editing as the experimental route to variant reclassification
• Approved and late-stage therapies and the delivery route each depends on
• Ex vivo against in vivo editing and their different risk profiles
• Lipid nanoparticle and AAV delivery constraints on what can be edited
• Large deletions, chromothripsis and translocations that simple assays miss
• p53 response, clonal selection and the tumorigenic risk it implies
• Regulatory expectations for off-target characterisation in an IND package
• N-of-1 therapies and the regulatory and cost problems they create
• Germline editing prohibitions and the international governance position
• Reading an AI-plus-CRISPR claim critically rather than accepting the press release
| Parameter | Requirement |
|---|---|
| Covered Tool / Platform | Benchling |
| Covered Tool / Platform | CRISPOR |
| Covered Tool / Platform | Cas-OFFinder |
| Covered Tool / Platform | SnapGene |
| Covered Tool / Platform | Addgene |
| Covered Tool / Platform | NCBI Primer-BLAST |
Based on 0 scholar submissions
No verified reviews published yet. Be the first to share your academic experience.
Your rating will help prospective scholars. Ratings below 3 stars are routed privately to the faculty mentor for immediate response.